This edition of Alzheimer's & Parkinson's Drug Development Summit has already taken place.
Search future editions →Events › B2B Event
B2B Event
14th edition
The 14th Alzheimer's & Parkinson's Drug Development Summit is an industry-focused event dedicated to accelerating neurodegenerative disease treatments, featuring content on protein aggregation, neuroinflammation, fluid-based biomarkers, and novel therapeutic interventions.
Exhibitor mix: Solution providers listed alphabetically; includes Bioneer A/S, BrainXell, C2N Diagnostics, FUJIFILM, KBI, Trailhead Biosystems, and Ricoh Biosciences.
Planning for next year?
A curated group of solution providers here. You probably care about 20–30. Tell us your ICP, we'll find them.
Request intelligence →Delivery within 24 hours · $1,250
⚠️ The exhibitor list for this event isn't publicly accessible yet. We'll work on it once you submit a request.
Venue
Hyatt Regency BostonHotel venue · ~900 people
The Hyatt Regency Boston is a modern, 4-star hotel located in the heart of downtown Boston, steps away from the Theater District and Financial District. Featuring over 30,000 square feet of versatile meeting and event space, it is a premier venue for corporate conferences, meetings, and social gatherings.
📍 One Avenue de Lafayette, Boston, MA 02111, US
Operated by Hyatt Hotels Corporation
Organizer
Hanson WadePE-backed · London, United Kingdom · Founded 2008
Hanson Wade is a global conference organizer and market intelligence provider focused primarily on the life sciences and biopharma sectors.
Why people attend
To discover next-generation neurodegenerative therapeutics, find translational research partners, explore fluid-based biomarkers, and network with large pharma/biotech developers.
Exhibitor categories
Sample matches
Filtered to a Series-B SaaS ICP. Your filter will be different.
Sample Match A
example.com
"Strong ICP match: Series B, EU expansion, VP Engineering and CTO attending."
Sample Match B
example.io
"Mid-stage SaaS with active GTM motion; product-led growth signals align with ICP."
████████ ██████
████████.io
"████████████████████████████████████████."
Submit your ICP
to unlock all matches
████████ ██████
████████.io
"████████████████████████████████████████."
Submit your ICP
to unlock all matches
Speakers
51 speakers at Alzheimer's & Parkinson's Drug Development Summit
Vice President, Biopharma Business Development · Alamar Biosciences Inc.
"NULISA Neurology Biomarker Platform – Brain-derived pTau217 & High-plex Neurodegenerative Disease & Neuroinflammatory Biomarker Analysis"
Chief Science Officer · CND Life Sciences
"Longitudinal Quantitative Studies of Phosphorylated Alpha-Synuclein"
Vice President - Clinical Development · Alzheon
"Oral Amyloid Oligomer Inhibition with ALZ-801: A Precision Medicine Approach for Early Alzheimer’s Disease"
Senior Director - Project Management · C2N Diagnostics LLC
"Novel Neurodegenerative Biomarkers for Precision Diagnostics and Clinical Trials"
Chief Innovation Officer · Atuka
"Aligning Preclinical InVivo Models of Parkinson’s Disease (PD) with Biological Classifications of PD"
CTO · Kunming Biomed International (KBI)
"CRO Services for CNS Oriented NHP Studies"
Senior Director - R&D · Ricoh Biosciences
"Decision-Grade Alzheimer’s Biology: Enhancing Translational Confidence with Biomarker-Driven Alzheimer’s iPSC Panels"
Applications & BD Manager · BrainXell
"Human iPSC-derived Neurons & Glia to Model Alzheimer’s & Parkinson’s Disease"
Chief Scientific Officer · Bioneer A/S
"A Human Neuronal Based Alpha-Synuclein Assay Useful for Drug Discovery"
Principal Scientist · Abbvie
"Session Chair"
Manager · Living with Parkinson's Disease Seminars
"Patient Perspectives in Neurodegeneration: Shaping the Future of Alzheimer’s & Parkinson’s Drug Development"
Director, Clinical Biomarkers · Prothena Corporation
"Roundtable Discussion: Harmonising Fluid‑Biomarker Assays Across Sites for Regulatory Confidence"
Head, Drug Development · Fuku Biotech
"Roundtable Discussion: Digital Wearable Sensors to Provide Continuous, Objective Motor Data & Unlock Faster, Leaner Parkinson’s Trials as Primary Endpoints"
VP Translational Medicine · Voyager Therapeutics Inc
"Deciphering the Landscape of Emerging Neurodegenerative Fluid Markers Beyond p-tau & α-Synuclein"
Associate Professor of Psychiatry & Neurology · University of Pittsburgh School of Medicine
"Workshop B | Reimagining Translational Validity: Optimizing In Vivo Models for Predictive Power in Alzheimer’s & Parkinson’s Drug Development"
Head of Precision Neurology & Neuroinflammation Cluster · Sanofi
"From Proteinopathies to Pathways: The Next Wave of Disease-Modifying Therapies in AD & PD – Beyond Aβ, Tau & α-Synuclein"
+ 35 more speakers at this event.
More events in United States
Frequently asked questions